Glucotrack prices $3.1M public offering at $2.04 per share

Glucotrack, Inc. (NASDAQ: GCTK) has priced a "best efforts" public offering expected to raise approximately $3.1 million in gross proceeds, before placement agent fees and offering expenses, according to a company statement.

The offering includes 169,388 shares of common stock at $2.04 per share. In lieu of common stock, certain investors will receive pre-funded warrants to purchase up to 1,350,220 shares at $2.039 per warrant. The offering was priced at-the-market under Nasdaq rules and is expected to close on or about September 25, 2026, subject to customary closing conditions.

Dawson James Securities, Inc. is acting as the sole placement agent for the offering.

The offering is being made pursuant to a registration statement on Form S-3 declared effective by the Securities and Exchange Commission on October 3, 2024.

Glucotrack operates Lōkahi Therapeutics, a biopharmaceutical platform company, and through its subsidiary Glucotrack Technologies, Inc., develops technologies for people with diabetes, including a long-term implantable continuous blood glucose monitoring system.

You May Also Be Interested In

• HCW Biologics prices $1.5M private placement with existing investor
• Autonomix Medical receives European patent for neural activity system
• Milestone Pharmaceuticals enrolls first Canadian patient in AFib trial